Yun Zhong
Stock Analyst at Wedbush
(0.55)
# 3,768
Out of 4,814 analysts
29
Total ratings
28%
Success rate
-17.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Reiterates: Neutral | $15 | $14.06 | +6.69% | 1 | Apr 1, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $70 | $46.32 | +51.12% | 2 | Mar 28, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Outperform | n/a | $3.16 | - | 1 | Mar 12, 2025 | |
| PASG Passage Bio | Assumes: Outperform | $4 | $0.31 | +1,173.89% | 2 | Nov 29, 2024 | |
| MLTX MoonLake Immunotherapeutics | Assumes: Outperform | $92 → $73 | $37.90 | +92.61% | 1 | Nov 5, 2024 | |
| RZLT Rezolute | Initiates: Outperform | $12 | $2.75 | +336.36% | 1 | Nov 5, 2024 | |
| AVXL Anavex Life Sciences | Maintains: Buy | $35 → $28 | $8.95 | +212.85% | 2 | Feb 9, 2023 | |
| TSHA Taysha Gene Therapies | Downgrades: Neutral | n/a | $1.25 | - | 2 | Feb 2, 2023 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $14 → $16 | $6.83 | +134.43% | 1 | Jan 18, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $125 → $160 | $53.79 | +197.45% | 11 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $6.33 | +452.92% | 1 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $700 | $4.15 | +16,767.47% | 2 | Jul 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $13.00 | +253.85% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.31 | +333.84% | 1 | May 5, 2021 |
Keros Therapeutics
Apr 1, 2025
Reiterates: Neutral
Price Target: $15
Current: $14.06
Upside: +6.69%
Protagonist Therapeutics
Mar 28, 2025
Reiterates: Outperform
Price Target: $70
Current: $46.32
Upside: +51.12%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Outperform
Price Target: n/a
Current: $3.16
Upside: -
Passage Bio
Nov 29, 2024
Assumes: Outperform
Price Target: $4
Current: $0.31
Upside: +1,173.89%
MoonLake Immunotherapeutics
Nov 5, 2024
Assumes: Outperform
Price Target: $92 → $73
Current: $37.90
Upside: +92.61%
Rezolute
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $2.75
Upside: +336.36%
Anavex Life Sciences
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $8.95
Upside: +212.85%
Taysha Gene Therapies
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.25
Upside: -
Amicus Therapeutics
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $6.83
Upside: +134.43%
Sarepta Therapeutics
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $53.79
Upside: +197.45%
Nov 1, 2022
Initiates: Buy
Price Target: $35
Current: $6.33
Upside: +452.92%
Jul 1, 2021
Downgrades: Hold
Price Target: $700
Current: $4.15
Upside: +16,767.47%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $13.00
Upside: +253.85%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $2.31
Upside: +333.84%